Gilead Sciences announced that the U.S. Patent and Trademark Office has reaffirmed one of four key patents for its HIV drug Viread. The patents are being reassessed after being challenged by the Public Patent Foundation, which has claimed prior art. The patent office will likely uphold the other three patents, an analyst said.

Related Summaries